SeamlessMD CEO Reflects on a Decade in Healthtech

SeamlessMD was founded in 2012 by Joshua Liu, Willie Kwok, and Philip Chen to provide a mobile-first platform for guiding patients through surgery. The company's first solution focused on colorectal surgery patients and was implemented at Baylor in Houston. To date, the Toronto-based startup has raised a total of $6.71 million over two funding rounds. The company’s platform is now one of the first patient engagement solutions with validated, turnkey integrations with major EHRs, including Epic, Oracle Cerner, and MEDITECH. This integration allows providers to enroll and monitor patients directly within their existing workflow, a critical step for adoption. For patients, the system can be integrated with portals like Epic's MyChart. For consumer health startups, the path to user acquisition often relies on building trust through valuable free features, as seen with apps like Calm and Headspace. Successful apps like Noom, which has over 45 million downloads, leverage behavioral science and data-driven personalization to foster long-term habit formation. These companies often pursue a multi-pronged growth strategy that extends beyond direct-to-consumer marketing to include partnerships with employers and insurers. Navigating health data privacy is a major hurdle. While HIPAA typically applies to healthcare providers and their business associates, many consumer-facing health apps fall outside its scope. This leaves user data governed by consumer privacy laws and the app's own policies. However, the FTC's Health Breach Notification Rule requires health apps not covered by HIPAA to notify users of data breaches, including unauthorized sharing with third-party advertisers. The journey from a technical founder to a CEO in the health tech space is fraught with challenges, including significant administrative burdens and the need to develop expertise across business operations, marketing, and sales. Solo founders, in particular, face higher failure rates due to psychological burnout, difficulty securing funding, and strategic blind spots that can arise from a lack of diverse perspectives. The "biohacking" and longevity sector is attracting significant venture capital, with a focus on extending "healthspan." Companies like NewLimit, co-founded by Coinbase CEO Brian Armstrong, are focused on epigenetic reprogramming and have raised substantial funding rounds. This area of the market is fueled by high-profile investors like Sam Altman and Peter Thiel, who are backing startups focused on cellular rejuvenation and AI-driven drug discovery for age-related diseases.